Current Clinical Trials
Randomized, blinded, placebo-controlled field study to determine the efficacy and safety of TANOVEA®-CA1 (rabacfosadine for injection) in dogs
Sponsor: VetDC, Inc.
TANOVEA®-CA1 (rabacfosadine for injection) is the first and only FDA conditionally approved drug for the treatment of lymphoma in dogs. This pivotal study is intended to provide the data to demonstrate substantial evidence of effectiveness as well as additional safety information in support of full FDA approval.
VC-014 is a randomized, multi-center, double-blinded, placebo-controlled study evaluating TANOVEA®-CA1 (rabacfosadine for injection) administered every three weeks for up to five treatments in dogs with lymphoma (either previously treated or untreated). In order to participate in the study, dogs must meet eligibility criteria described in the protocol. The study is fully funded by the Sponsor, and owners will be offered a clinic credit towards additional treatment in the event of disease progression. For more information, call our Culver City office at (310) 558-6120 and ask to speak with trial aide Amber.
Canine Osteosarcoma Vaccine, Live Listeria Vector (COV-LLV)
Our Culver City office is participating in a study to evaluate the Canine Osteosarcoma Vaccine, Live Listeria Vector (COV-LLV), a conditionally licensed product for dogs with osteosarcoma who have undergone amputation and chemotherapy. For participation, your dog must meet the eligibility requirements listed in the study protocol. Your veterinarian will confirm eligibility by reviewing your dog’s medical history, performing a physical exam, taking thoracic radiographs, and submitting routine blood and urine testing. All dogs enrolled in the study will be treated with the immunotherapy.
If you have any questions or are interested in discussing the trial, please email us at LA.email@example.com with the subject line "COV-LLV Question" or call our Culver City office at (310) 558-6120 and ask to speak with trial aide Amber.
Canine Osteosarcoma Autologous Therapeutic Immunotherapy
Veterinary Cancer Group is currently enrolling cases for a partially funded clinical trial to evaluate safety and efficacy of an autologous (made from a patient’s own tumor) therapeutic immunotherapy vaccine (K9-ACV) in combination with amputation and chemotherapy for the treatment of canine appendicular osteosarcoma. This novel concept is being explored to examine extended lifespan beyond standard of care for canine cancer patients. The current standard of care for canine appendicular osteosarcoma patients is amputation and chemotherapy (generally either carboplatin chemotherapy or Adriamycin chemotherapy).
This immunotherapy vaccine is provided by MediVet Biologics (www.medivetbiologics.com) and will be available via a convenient visit to your treating veterinarian VCG oncologist at the Woodland Hills, South Bay or Tustin locations. This immunotherapy vaccine is not currently being offered at our Culver City location.
Inclusion criteria for this trial
(this list is meant to be a guide and is not exhaustive – final inclusion/exclusion is determined by the on site trial investigator.)
- Canine patients who have been diagnosed or presumptively diagnosed with osteosarcoma of the limbs
- Canine patients who have not yet undergone amputation for osteosarcoma (this is critical for trial inclusion)
- Owners must elect amputation and chemotherapy (carboplatin chemotherapy) for their dog in addition to receiving the autologous tumor vaccine (K9 ACV).
- No pulmonary metastatic disease (spread to the lungs)
- No additional major medical conditions that would prevent a patient from undergoing surgery and chemotherapy
(Prior to acceptance into any trial, all candidates are required to have a consultation to determine eligibility. The fee for the consultation is the responsibility of the pet owner.)
Visit this link for more information about current pet clinical trials:
American Veterinary Medical Association's Animal Health Studies Database.
(edited January 2019)